These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 1638937)

  • 1. Cytologic diagnosis of malignant mesothelioma in serous effusions using an antimesothelial-cell antibody.
    Donna A; Betta PG; Bellingeri D; Tallarida F; Pavesi M; Pastormerlo M
    Diagn Cytopathol; 1992; 8(4):361-5. PubMed ID: 1638937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of HBME-1 immunostaining in serous effusions.
    Ascoli V; Carnovale-Scalzo C; Taccogna S; Nardi F
    Cytopathology; 1997 Oct; 8(5):328-35. PubMed ID: 9313985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
    Barberis MC; Faleri M; Veronese S; Casadio C; Viale G
    Acta Cytol; 1997; 41(6):1757-61. PubMed ID: 9390137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
    Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
    Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining.
    Kitazume H; Kitamura K; Mukai K; Inayama Y; Kawano N; Nakamura N; Sano J; Mitsui K; Yoshida S; Nakatani Y
    Cancer; 2000 Feb; 90(1):55-60. PubMed ID: 10692217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of malignant cells in serous effusions using a panel of monoclonal antibodies Ber-EP4, MCA-b-12 and EMA.
    Stoop JA; Hendriks JG; Berends D
    Cytopathology; 1992; 3(5):297-302. PubMed ID: 1288655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis.
    Stevens MW; Leong AS; Fazzalari NL; Dowling KD; Henderson DW
    Diagn Cytopathol; 1992; 8(4):333-41. PubMed ID: 1638933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
    Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
    Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic problems in serous effusions.
    Bedrossian CW
    Diagn Cytopathol; 1998 Aug; 19(2):131-7. PubMed ID: 9702493
    [No Abstract]   [Full Text] [Related]  

  • 10. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
    Kobzik L; Antman KH; Warhol MJ
    Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
    Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
    Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinction between cells in serous effusions using a panel of antibodies.
    Lauritzen AF
    Virchows Arch A Pathol Anat Histopathol; 1987; 411(3):299-304. PubMed ID: 2441518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
    Su XY; Li GD; Liu WP; Xie B; Jiang YH
    Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma.
    Vettukattil R; Hetland TE; Flørenes VA; Kærn J; Davidson B; Bathen TF
    Hum Pathol; 2013 Sep; 44(9):1859-66. PubMed ID: 23656974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.
    Chhieng DC; Yee H; Schaefer D; Cangiarella JF; Jagirdar J; Chiriboga LA; Jagirdar J; Chiriboga LA; Cohen JM
    Cancer; 2000 Jun; 90(3):194-200. PubMed ID: 10896333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytologic presentation of malignant mesothelioma in pleural effusions.
    Pedio G; Landolt-Weber U
    Exp Cell Biol; 1988; 56(4):211-6. PubMed ID: 3203820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
    Afify A; Zhou H; Howell L; Paulino AF
    Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
    Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
    Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved identification of malignant cells in serous effusions using a small, robust panel of antibodies on paraffin-embedded cell suspensions.
    Grefte JM; de Wilde PC; Salet-van de Pol MR; Tomassen M; Raaymakers-van Geloof WL; Bulten J
    Acta Cytol; 2008; 52(1):35-44. PubMed ID: 18323273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3.
    Martin SE; Moshiri S; Thor A; Vilasi V; Chu EW; Schlom J
    Am J Clin Pathol; 1986 Jul; 86(1):10-8. PubMed ID: 3524191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.